Price
CHART BY
Frequently asked questions
What is BioNTech SE ADR's market capitalization?
The market capitalization of BioNTech SE ADR is $24.10B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for BioNTech SE ADR?
BioNTech SE ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$9.011. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BioNTech SE ADR's stock?
Currently, 21 analysts cover BioNTech SE ADR's stock, with a consensus target price of $118.22. Analyst ratings provide insights into the stock's expected performance.
What is BioNTech SE ADR's revenue over the trailing twelve months?
Over the trailing twelve months, BioNTech SE ADR reported a revenue of $3.55B.
What is the EBITDA for BioNTech SE ADR?
BioNTech SE ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$428.63M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BioNTech SE ADR?
BioNTech SE ADR has a free cash flow of $550.64M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BioNTech SE ADR have, and what sector and industry does it belong to?
BioNTech SE ADR employs approximately 7,807 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of BioNTech SE ADR's shares?
The free float of BioNTech SE ADR is 250.13M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $24.10B
- EPS (TTM)
- -$9.011
- Free Float
- 250.13M
- Revenue (TTM)
- $3.55B
- EBITDA (TTM)
- -$428.63M
- Free Cashflow (TTM)
- $550.64M
Pricing
- 1D span
- $98.77$99.82
- 52W span
- $79.52$123.96
Analyst Ratings
The price target is $118.22 and the stock is covered by 21 analysts.
Buy
14
Hold
6
Sell
1
Information
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
- Employees
- 7,807
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- BNTX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet